Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

t is being prepared.

?These three Phase II clinical trials sponsored by NCI are components of a clinical trials program designed to identify signals of clinical activity of ispinesib across multiple tumor types,? stated Dr. Andrew A. Wolff, Cytokinetics Senior Vice President of Clinical Research and Development and Chief Medical Officer. ?Although these three trials did not meet the protocol-specified criteria for progression, we are encouraged by the anti-cancer activity of ispinesib observed to date in three other Phase II trials in breast, ovarian and non-small cell lung cancers. Based on these data, we plan to move forward in further clinical development of ispinesib with a focused approach to the potential treatment of breast cancer with ispinesib.?

Clinical Trials of Ispinesib

Ispinesib has been the subject of a broad Phase II clinical trials program under the sponsorship of GlaxoSmithKline (GSK) and is also being developed in collaboration with the NCI. GSK has sponsored three Phase II clinical trials, one evaluating ispinesib as second- or third-line treatment for patients with locally advanced or metastatic breast cancer, one evaluating ispinesib as second-line treatment for patients with non-small cell lung cancer, and one evaluating ispinesib as second-line treatment for patients with advanced ovarian cancer. Enrollment in all of these trials has been closed. To date, clinical activity with ispinesib has been observed in breast cancer, in non-small cell lung cancer, and ovarian cancer with the more robust clinical activity observed in a Phase II clinical trial evaluating ispinesib in the treatment of metastatic breast cancer patients that have failed treatment with taxanes and anthracyclines. In this clinical trial, The best overall responses observed with ispinesib were partial responses in 4 of 45 evaluable patients as measured by the RECIST criteria. Responses were confirmed by independent radiology review and were seen in
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:5/24/2013)... , May 24, 2013 ... administration for systemic delivery of therapeutic agents has been ... inhalation drug delivery showing significant promise. The crucial formulation ... a delivery device play a major role in the ... made in the development of new formulation techniques and ...
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 Neurocrine ... Kevin Gorman , President and Chief Executive ... Bank 38 th Annual dbAccess Health Care Conference in ... Thursday, May 30 at 11:20 a.m. Eastern Time / 8:20 ... be accessed on the Company,s website at http://www.neurocrine.com . ...
(Date:5/23/2013)... Minn. , May 23, 2013  MGC Diagnostics ... a global medical technology company, today scheduled a conference ... quarter of fiscal year 2013, ended April 30, 2013. ... Thursday, May 30, 2013. The Company will report financial ... after the markets close on Thursday, May 30, 2013. ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2
(Date:5/24/2013)... mutations central to the development of infantile myofibromatosis (IM)a ... and soft tissuemay provide new therapeutic targets, according to ... Sinai. The findings, published in the American Journal ... options for this debilitating disease, for which the only ... tumors. , IM is an inheritied disorder that develops ...
(Date:5/24/2013)... Mike Stoler believes that there is much to be ... York. That’s why he hosts “Building New York—New ... And that’s why he invited Robert Glazer, Chief Executive ... single specialty practice in the greater New York area, ... and sub-specialists service communities throughout New York and New ...
(Date:5/24/2013)... May 24, 2013 6Webs.com has educated ... out a home security monitoring provider. The ... 6Webs.com the useful resource consumers prefer for unbiased and ... their evaluations of the leading wireless home security system ... are rated on a number of key factors including ...
(Date:5/24/2013)... Bethesda, MD (PRWEB) May 24, 2013 ... to its growing base of clients. As a result ... reports a presence in 20 states around the ... providing medical transcription services to the healthcare industry ... nurses who use their years of clinical work ...
(Date:5/24/2013)... (HealthDay News) -- The number of U.S. patients ... time in an emergency room has increased by ... The study, conducted by researchers at the George ... Services in Washington, D.C., found that patients wait ... before being admitted to the ICU. The researchers ...
Breaking Medicine News(10 mins):Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4Health News:2013 Best Wireless Security System Providers Reported by 6Webs.com 2Health News:The Dictation Source Signs Two National Hospital Chains 2Health News:The Dictation Source Signs Two National Hospital Chains 3Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2
... ... ... contributions of voluntary plasma donors and the issue of treating critically ill ... proclaimed August "Plasma Protein Therapies Month" in the Lone Star State. , , ,"Patients ...
... ... on top of current events in the health care industry. , ... Seattle, Washington (PRWEB) August 19, 2009 -- Today, All Allied Health Schools ... helps students keep up with the latest developments in the health care industry--and how these changes ...
... , ANN ARBOR, Mich., Aug. 19 The median profit ... of 2008 to 3.1 percent in the first quarter of 2009, according ... , The recovery has been broad-based, with all classes ... major teaching hospitals -- showing positive median margins. , ...
... ... the Causes of this Growing Trend , ... Jacksonville, Fla. (Vocus) August 18, 2009 -- A recent National Institute of Health ... the growing popularity of alternative therapies for both healthcare treatment and prevention. ...
... A nearly two-decade trend that is stripping away employer-provided ... continue and could soon hit an even deeper pool ... Illinois elder law expert warns. Richard L. Kaplan ... largely from a 1992 change in accounting standards that ...
... , NEW YORK, NY, Aug. 18 /PRNewswire-FirstCall/ - (OTCBB: ... that identifies, acquires, and develops novel drug targets that ... Whiteman as its Chief Executive Officer. , Mr. Whiteman, ... London School of Economics . He will provide ...
Cached Medicine News:Health News:Plasma protein Therapies Association Focuses Attention on Donors and Facilities 2Health News:Plasma protein Therapies Association Focuses Attention on Donors and Facilities 3Health News:All Allied Health Schools Launches "Health Care Community" 2Health News:All Allied Health Schools Launches "Health Care Community" 3Health News:Thomson Reuters Study Finds Impact of Recession Easing on U.S. Hospitals 2Health News:Thomson Reuters Study Finds Impact of Recession Easing on U.S. Hospitals 3Health News:Alternative Therapies And Their Growing Popularity 2Health News:Alternative Therapies And Their Growing Popularity 3Health News:Alternative Therapies And Their Growing Popularity 4Health News:Retirees' health-care benefits at risk, study warns 2Health News:Retirees' health-care benefits at risk, study warns 3Health News:GENova names Aaron Whiteman as CEO 2Health News:GENova names Aaron Whiteman as CEO 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: